메뉴 건너뛰기




Volumn 130, Issue 6, 2014, Pages 496-507

Inhibition of phosphodiesterase 2 augments cGMP and cAMP signaling to ameliorate pulmonary hypertension

Author keywords

Cyclic nucleotide; Natriuretic peptide; Nitric oxide; Phosphodiesterase inhibitor; Pulmonary hypertension

Indexed keywords

CYCLIC NUCLEOTIDE; NATRIURETIC PEPTIDE; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITOR; PULMONARY HYPERTENSION;

EID: 84905563804     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.114.009751     Document Type: Article
Times cited : (64)

References (44)
  • 1
    • 33748998458 scopus 로고    scopus 로고
    • Pulmonary arterial hypertension
    • McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation. 2006;114:1417-1431.
    • (2006) Circulation , vol.114 , pp. 1417-1431
    • McLaughlin, V.V.1    McGoon, M.D.2
  • 2
    • 5344233478 scopus 로고    scopus 로고
    • Pulmonary arterial hypertension
    • Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004;351:1655-1665.
    • (2004) N Engl J Med. , vol.351 , pp. 1655-1665
    • Farber, H.W.1    Loscalzo, J.2
  • 7
    • 84863519076 scopus 로고    scopus 로고
    • An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry
    • Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012;142:448-456.
    • (2012) Chest , vol.142 , pp. 448-456
    • Benza, R.L.1    Miller, D.P.2    Barst, R.J.3    Badesch, D.B.4    Frost, A.E.5    McGoon, M.D.6
  • 8
    • 84880678637 scopus 로고    scopus 로고
    • The role of cGMP in the physiological and molecular responses of the right ventricle to pressure overload
    • Janssen W, Schermuly RT, Kojonazarov B. The role of cGMP in the physiological and molecular responses of the right ventricle to pressure overload. Exp Physiol. 2013;98:1274-1278.
    • (2013) Exp Physiol. , vol.98 , pp. 1274-1278
    • Janssen, W.1    Schermuly, R.T.2    Kojonazarov, B.3
  • 9
    • 79953686516 scopus 로고    scopus 로고
    • New perspectives for the treatment of pulmonary hypertension
    • Baliga RS, MacAllister RJ, Hobbs AJ. New perspectives for the treatment of pulmonary hypertension. Br J Pharmacol. 2011;163:125-140.
    • (2011) Br J Pharmacol. , vol.163 , pp. 125-140
    • Baliga, R.S.1    MacAllister, R.J.2    Hobbs, A.J.3
  • 11
    • 33748686575 scopus 로고    scopus 로고
    • Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use
    • Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev. 2006;58:488-520.
    • (2006) Pharmacol Rev. , vol.58 , pp. 488-520
    • Bender, A.T.1    Beavo, J.A.2
  • 12
    • 22744433270 scopus 로고    scopus 로고
    • High lung PDE5: A strong basis for treating pulmonary hypertension with PDE5 inhibitors
    • Corbin JD, Beasley A, Blount MA, Francis SH. High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors. Biochem Biophys Res Commun. 2005;334:930-938.
    • (2005) Biochem Biophys Res Commun. , vol.334 , pp. 930-938
    • Corbin, J.D.1    Beasley, A.2    Blount, M.A.3    Francis, S.H.4
  • 13
    • 12244282450 scopus 로고    scopus 로고
    • Increased expression of the cGMPinhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension
    • Murray F, MacLean MR, Pyne NJ. Increased expression of the cGMPinhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension. Br J Pharmacol. 2002;137:1187-1194.
    • (2002) Br J Pharmacol. , vol.137 , pp. 1187-1194
    • Murray, F.1    MacLean, M.R.2    Pyne, N.J.3
  • 14
    • 0037741441 scopus 로고    scopus 로고
    • Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension
    • Sebkhi A, Strange JW, Phillips SC, Wharton J, Wilkins MR. Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation. 2003;107:3230-3235.
    • (2003) Circulation , vol.107 , pp. 3230-3235
    • Sebkhi, A.1    Strange, J.W.2    Phillips, S.C.3    Wharton, J.4    Wilkins, M.R.5
  • 15
    • 33846200014 scopus 로고    scopus 로고
    • Expression and activity of cAMP phosphodiesterase isoforms in pulmonary artery smooth muscle cells from patients with pulmonary hypertension: Role for PDE1
    • Murray F, Patel HH, Suda RY, Zhang S, Thistlethwaite PA, Yuan JX, Insel PA. Expression and activity of cAMP phosphodiesterase isoforms in pulmonary artery smooth muscle cells from patients with pulmonary hypertension: role for PDE1. Am J Physiol. 2007;292:L294-L303.
    • (2007) Am J Physiol. , vol.292
    • Murray, F.1    Patel, H.H.2    Suda, R.Y.3    Zhang, S.4    Thistlethwaite, P.A.5    Yuan, J.X.6    Insel, P.A.7
  • 19
    • 11144258648 scopus 로고    scopus 로고
    • CAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling
    • Phillips PG, Long L, Wilkins MR, Morrell NW. cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling. Am J Physiol. 2005;288:L103-L115.
    • (2005) Am J Physiol. , vol.288
    • Phillips, P.G.1    Long, L.2    Wilkins, M.R.3    Morrell, N.W.4
  • 21
    • 0030712081 scopus 로고    scopus 로고
    • The GAF domain: An evolutionary link between diverse phototransducing proteins
    • Aravind L, Ponting CP. The GAF domain: an evolutionary link between diverse phototransducing proteins. Trends Biochem Sci. 1997;22:458-459.
    • (1997) Trends Biochem Sci. , vol.22 , pp. 458-459
    • Aravind, L.1    Ponting, C.P.2
  • 23
    • 35448930310 scopus 로고    scopus 로고
    • Differential regulation of endothelial cell permeability by cGMP via phosphodiesterases 2 and 3
    • Surapisitchat J, Jeon KI, Yan C, Beavo JA. Differential regulation of endothelial cell permeability by cGMP via phosphodiesterases 2 and 3. Circ Res. 2007;101:811-818.
    • (2007) Circ Res. , vol.101 , pp. 811-818
    • Surapisitchat, J.1    Jeon, K.I.2    Yan, C.3    Beavo, J.A.4
  • 24
    • 0030077686 scopus 로고    scopus 로고
    • Erythro-9-(2-hydroxy-3-nonyl) adenine inhibits cyclic-3æ, 5æ-guanosine monophosphatestimulated phosphodiesterase to reverse hypoxic pulmonary vasoconstriction in the perfused rat lung
    • Haynes J Jr, Killilea DW, Peterson PD, Thompson WJ. Erythro-9-(2-hydroxy- 3-nonyl) adenine inhibits cyclic-3æ, 5æ-guanosine monophosphatestimulated phosphodiesterase to reverse hypoxic pulmonary vasoconstriction in the perfused rat lung. J Pharmacol Exp Ther. 1996;276:752-757.
    • (1996) J Pharmacol Exp Ther. , vol.276 , pp. 752-757
    • Haynes Jr., J.1    Killilea, D.W.2    Peterson, P.D.3    Thompson, W.J.4
  • 27
    • 0037458096 scopus 로고    scopus 로고
    • Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic Peptide activity
    • Zhao L, Mason NA, Strange JW, Walker H, Wilkins MR. Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic Peptide activity. Circulation. 2003;107:234-237.
    • (2003) Circulation , vol.107 , pp. 234-237
    • Zhao, L.1    Mason, N.A.2    Strange, J.W.3    Walker, H.4    Wilkins, M.R.5
  • 28
    • 84862125705 scopus 로고    scopus 로고
    • Dietary nitrate ameliorates pulmonary hypertension: Cytoprotective role for endothelial nitric oxide synthase and xanthine oxidoreductase
    • Baliga RS, Milsom AB, Ghosh SM, Trinder SL, Macallister RJ, Ahluwalia A, Hobbs AJ. Dietary nitrate ameliorates pulmonary hypertension: cytoprotective role for endothelial nitric oxide synthase and xanthine oxidoreductase. Circulation. 2012;125:2922-2932.
    • (2012) Circulation , vol.125 , pp. 2922-2932
    • Baliga, R.S.1    Milsom, A.B.2    Ghosh, S.M.3    Trinder, S.L.4    Macallister, R.J.5    Ahluwalia, A.6    Hobbs, A.J.7
  • 30
    • 84862218009 scopus 로고    scopus 로고
    • Contributions of nitric oxide synthases, dietary nitrite/nitrate, and other sources to the formation of NO signaling products
    • Milsom AB, Fernandez BO, Garcia-Saura MF, Rodriguez J, Feelisch M. Contributions of nitric oxide synthases, dietary nitrite/nitrate, and other sources to the formation of NO signaling products. Antioxid Redox Signal. 2012;17:422-432.
    • (2012) Antioxid Redox Signal , vol.17 , pp. 422-432
    • Milsom, A.B.1    Fernandez, B.O.2    Garcia-Saura, M.F.3    Rodriguez, J.4    Feelisch, M.5
  • 31
    • 20444397009 scopus 로고    scopus 로고
    • Local atrial natriuretic peptide signaling prevents hypertensive cardiac hypertrophy in endothelial nitric-oxide synthase-deficient mice
    • Bubikat A, De Windt LJ, Zetsche B, Fabritz L, Sickler H, Eckardt D, Godecke A, Baba HA, Kuhn M. Local atrial natriuretic peptide signaling prevents hypertensive cardiac hypertrophy in endothelial nitric-oxide synthase-deficient mice. J Biol Chem. 2005;280:21594-21599.
    • (2005) J Biol Chem. , vol.280 , pp. 21594-21599
    • Bubikat, A.1    De Windt, L.J.2    Zetsche, B.3    Fabritz, L.4    Sickler, H.5    Eckardt, D.6    Godecke, A.7    Baba, H.A.8    Kuhn, M.9
  • 32
    • 0024282457 scopus 로고
    • Role of endopeptidase-24.11 in the inactivation of atrial natriuretic peptide
    • Kenny AJ, Stephenson SL. Role of endopeptidase-24.11 in the inactivation of atrial natriuretic peptide. FEBS Lett. 1988;232:1-8.
    • (1988) FEBS Lett. , vol.232 , pp. 1-8
    • Kenny, A.J.1    Stephenson, S.L.2
  • 34
    • 0042859823 scopus 로고    scopus 로고
    • Cyclic GMP phosphodiesterases and regulation of smooth muscle function
    • Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA. Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res. 2003;93:280-291.
    • (2003) Circ Res. , vol.93 , pp. 280-291
    • Rybalkin, S.D.1    Yan, C.2    Bornfeldt, K.E.3    Beavo, J.A.4
  • 35
    • 33646795266 scopus 로고    scopus 로고
    • Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes
    • Castro LR, Verde I, Cooper DM, Fischmeister R. Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes. Circulation. 2006;113:2221-2228.
    • (2006) Circulation , vol.113 , pp. 2221-2228
    • Castro, L.R.1    Verde, I.2    Cooper, D.M.3    Fischmeister, R.4
  • 37
    • 70049112901 scopus 로고    scopus 로고
    • Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)
    • Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30:2493-2537.
    • (2009) Eur Heart J. , vol.30 , pp. 2493-2537
    • Galie, N.1    Hoeper, M.M.2    Humbert, M.3    Torbicki, A.4    Vachiery, J.L.5    Barbera, J.A.6    Beghetti, M.7    Corris, P.8    Gaine, S.9    Gibbs, J.S.10    Gomez-Sanchez, M.A.11    Jondeau, G.12    Klepetko, W.13    Opitz, C.14    Peacock, A.15    Rubin, L.16    Zellweger, M.17    Simonneau, G.18
  • 38
    • 84899974051 scopus 로고    scopus 로고
    • Differential regulation of C-type natriuretic peptide-induced cGMP and functional responses by PDE2 and PDE3 in failing myocardium [published online ahead of print January 15, 2014]
    • DOI:10.1007/s00210-013-0953-1
    • Moltzau LR, Meier S, Aronsen JM, Afzal F, Sjaastad I, Skomedal T, Osnes JB, Levy FO, Qvigstad E. Differential regulation of C-type natriuretic peptide-induced cGMP and functional responses by PDE2 and PDE3 in failing myocardium [published online ahead of print January 15, 2014]. Naunyn Schmiedebergs Arch Pharmacol. 2014;387:407-417. DOI:10.1007/s00210-013-0953-1.
    • (2014) Naunyn Schmiedebergs Arch Pharmacol. , vol.387 , pp. 407-417
    • Moltzau, L.R.1    Meier, S.2    Aronsen, J.M.3    Afzal, F.4    Sjaastad, I.5    Skomedal, T.6    Osnes, J.B.7    Levy, F.O.8    Qvigstad, E.9
  • 40
    • 0032814621 scopus 로고    scopus 로고
    • Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: Insights from the Flolan International Randomized Survival Trial (FIRST)
    • O'Connor CM, Gattis WA, Uretsky BF, Adams KF Jr, McNulty SE, Grossman SH, McKenna WJ, Zannad F, Swedberg K, Gheorghiade M, Califf RM. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1999;138(pt 1):78-86.
    • (1999) Am Heart J. , vol.138 , Issue.PART 1 , pp. 78-86
    • O'Connor, C.M.1    Gattis, W.A.2    Uretsky, B.F.3    Adams Jr., K.F.4    McNulty, S.E.5    Grossman, S.H.6    McKenna, W.J.7    Zannad, F.8    Swedberg, K.9    Gheorghiade, M.10    Califf, R.M.11


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.